ClinicalTrials.gg
RecruitingNCT07530757Updated Sep 11, 2026

SuperCAP Program to Improve Cognition and Daily Functioning in Post-COVID-19 Condition

An interventional study of SuperCAP intervention program and Psychoeducational intervention in Post COVID Condition, sponsored by Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain — 13 open to participants now, 16 under way, 1 of them phase 3. Post-Acute COVID-19 Syndrome · Spain.

Planned enrollment
8th of 39
100 · median 60
Started
2026
with 4 others
No phase
31 of 52
7 open now
Primary completion
2026-11
later than 10 of 15 live
Registered
47th of 52
by date
Lead sponsor
4 of 52
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

Among the 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain, this one is the 8th largest by planned enrollment of the 39 interventional ones that give a count, is one of 5 that started in 2026, is one of 31 with no phase, reaches primary completion later than 10 of the 15 other live ones, and was the 47th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

13 of the 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain, or all of them as a file.
02

Study summary

The goal of this study is to determine whether the SuperCAP intervention program is superior to control in reducing disability from baseline to the post-intervention assessment in people with Post-COVID-19 Condition.

The main question it aims to answer is whether participants assigned to SuperCAP experience a greater reduction in disability, defined as an improvement of at least 5 points on the WHODAS 2.0 from baseline to the post-intervention visit, compared with participants in the control group.

Participants assigned to the SuperCAP intervention will undergo a series of sessions that include psychoeducation, adaptive cognitive training exercises, fatigue self-management strategies, and multidisciplinary content.

Read the detailed description

-COVID-19 Condition (PCC) is a major public health challenge, with cognitive impairment and fatigue among its most prevalent and disabling symptoms, leading to substantial limitations in quality of life and daily functioning. Digital health solutions provide an opportunity to expand access to structured, evidence-informed care. SuperCAP was developed as a multidisciplinary digital therapeutic program to support cognitive and functional recovery in individuals with PCC. A randomized pilot study demonstrated its feasibility and acceptability, supporting the conduct of a larger randomized controlled trial to evaluate its efficacy on disability and cognitive outcomes.

Participants will be randomized (1:1) to receive the digital intervention (SuperCAP) or Standard of Care (SoC) during 13 weeks, followed by a 12-week observation period.

The primary objective is to determine whether the SuperCAP intervention program is superior to control in reducing disability from baseline to the post-intervention assessment.

The secondary objectives include evaluating the effects of SuperCAP on quality of life, daily functioning, cognitive and emotional outcomes, the durability of these effects at follow-up, and the feasibility and acceptability of program implementation.

03

Conditions studied

  • Post COVID Condition

Keywords

  • Post COVID Condition
  • Long COVID
  • SuperCAP
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of PCC, defined as the presence of three or more symptoms associated with COVID-19 infection for at least three months, not explained by other diseases.
  • Age 18 to 65 years.
  • Willingness to participate in an app-based intervention program aimed at improving daily Functioning in People Living with PCC.
  • Evidence of patient-reported cognitive difficulties emerging after COVID-19, operationalized as a WHODAS 2.0 Cognition Domain (D1) score > 6 at baseline via RedCAP.
  • Digital proficiency defined as scoring ≥4 on MDPQ-16 item 2a (sending emails) and ≥3 on item 6a (using the device's app store) via RedCAP.
  • Self-reported ability to use a mobile application for approximately 15 minutes per day, 5 days per week, considering their current symptoms.
  • Possession of a personal smartphone compatible with the study mobile application (eSalut), with sufficient storage space and operating system version required for installation.

Exclusion criteria

Exclusion Criteria:

  • Inability to undergo neuropsychological tests or additional assessments.
  • Prior use of the SuperCAP program.
  • Current participation in a trial or program aimed at improving PCC symptoms.
  • Any condition that, in the investigator's opinion, could make participation unsafe, complicate interpretation of study results, interfere with achievement of study objectives, or otherwise affect the participant's ability to complete the study.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    SuperCAP Arm

    The intervention comprises 60 sessions delivered over 12 weeks (5 sessions/week), with flexibility up to 15 weeks to accommodate symptom fluctuation. Each session follows a standardized structure to reinforce self-management and cognitive engagement. The sessions includes psychoeducation, adaptive cognitive training exercises, fatigue self-management strategies, and multidisciplinary content.

    Device: SuperCAP intervention program

  • Active comparator
    Standard of Care Arm

    The Standard of Care consists in a psychoeducational intervention on the cognitive disorders and fatigue associated with long COVID, and general guidelines on how to manage these symptoms so that they have the least possible impact on daily life.

    Other: Psychoeducational intervention

Interventions

  • DeviceSuperCAP intervention program

    The SuperCAP (Supervised Computerized Active Program) is an online, multidimensional therapeutic program integrated into eSalut, the Catalan Institute of Health's digital platform, designed to improve daily functioning and quality of life in individuals with PCC who experience cognitive symptoms

  • OtherPsychoeducational intervention

    The psychoeducational intervention is a non-pharmacological interventions that teach practical strategies to help individuals with the cognitive disorders and fatigue associated with long COVID and provide general guidelines on how to manage these symptoms so that they have the least possible impact on daily life.

06

What researchers measure

Primary outcomes

  1. To determine whether the SuperCAP intervention program is superior to control in reducing disability.

    Change in total WHODAS 2.0 score from baseline to post-intervention.

    Time frame: From baseline (week 0) to the post-intervention assessment (week 13).

Secondary outcomes

  1. To assess whether the SuperCAP intervention leads to greater improvements in quality of life compared with control.

    Change in EuroQol 5 Dimensions (EQ-5D) score from -0,654 to 1 where higher scores mean better outcome.

    Time frame: From baseline (week 0) to post-intervention (week 13)

  2. To assess whether the SuperCAP intervention leads to greater improvements in instrumental daily functioning compared with control.

    Change in Instrumental Activities of Daily Living (IADL) score from 0 to 8 where higher score mean better outcomes.

    Time frame: From baseline (week 0) to post-intervention (week 13).

  3. To evaluate whether the intervention improves performance-based cognitive measures.

    Change in Montreal Cognitive Assessment (MoCA) total score from 0 to 30 where higher scores mean better outcomes.

    Time frame: From baseline (week 0) to post-intervention (week 13).

  4. To evaluate whether the intervention improves patient-reported cognitive functioning.

    Change in subjective cognitive functioning in daily life by Memory Failures of Everyday Questionnaire (MFE-30) with scores from 0 to 120 where higher scores mean worse outcomes.

    Time frame: From baseline (week 0) to post-intervention (week 13).

  5. To assess reductions in depressive symptoms following the intervention.

    Change in Patient Health Questionnaire-9 (PHQ-9) with scores from 0 to 27 where higher scores means worse outcomes.

    Time frame: From baseline (week 0) to post-intervention (week 13)

  6. To assess reductions in anxiety symptoms following the intervention.

    Change in Generalized Anxiety Disorder-7 (GAD-7) score from 0 to 21 where higher scores mean worse outcomes.

    Time frame: From baseline (week 0) to post-intervention (week 13).

  7. To determine whether improvements in functional outcomes are sustained at follow-up.

    Change in World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) score from 0 to 144 where higher scores mean worse outcomes.

    Time frame: From post-intervention (week 13) to follow-up (week 25).

  8. To determine whether improvements in cognitive outcomes are sustained at follow-up.

    Change in Montreal Cognitive Assessment (MoCA) score from 0 to 30 where higher scores mean better outcomes.

    Time frame: From post-intervention (week 13) to follow-up (week 25).

  9. To determine whether improvements in emotional outcomes are sustained at follow-up.

    Change in EuroQol 5 Dimensions (EQ-5D) score from -0,654 to 1 where higher scores mean better outcomes.

    Time frame: From post-intervention (week 13) to follow-up (week 25).

  10. To evaluate feasibility of implementation, including adherence to the program.

    Program adherence captured through platform telemetry.

    Time frame: From post-intervention (week 13) to follow-up (week 25)

  11. To evaluate feasibility of implementation, including usability.

    Usability measured by System Usability Score (SUS) score from 0 to 100 where higher scores mean better outcomes.

    Time frame: From post-intervention (week 13) to follow-up (week 25)

  12. To evaluate feasibility of implementation, including satisfaction and retention.

    Participant satisfaction and perceived benefit will be assessed through a brief set of items evaluating overall satisfaction with the program, perceived usefulness and perceived improvement in daily functioning.

    Time frame: From post-intervention (week 13) to follow-up (week 25).

  13. To explore indicators of acceptability.

    Acceptability assessed using the Acceptability of Intervention Measure (AIM) scale which goes from 1 to 5 and higher scores mean better outcomes.

    Time frame: From post-intervention (week 13) to follow-up (week 25).

  14. To explore indicators of appropriateness.

    Appropriateness assessed using Intervention Appropriateness Measure (IAM) scale which goes from 1 to 5 where higher scores mean better outcomes.

    Time frame: From post-intervention (week 13) to follow-up (week 25).

  15. To explore indicators of implementation.

    Feasibility assessed using the Feasibility of Intervention Measure (FIM) scale which goes from 1 to 5 and higher scores mean better outcomes.

    Time frame: From post-intervention (week 13) to follow-up (week 25).

  16. To explore preliminary economic feasibility indicators.

    Economic feasibility will be explored through resource-use variables professional time required for support or monitoring, number and type of user support contacts or technical incidents requiring intervention).

    Time frame: From post-intervention (week 13) to follow-up (week 25).

07

Study locations

1 of 1 sites recruiting
  • Fundació Lluita contra les Infeccions - Hospital Universitari Germans Trias i Pujol
    Badalona, Barcelona 08916, Spain
    Recruiting
    • Fundacion Fls De Lucha Contra El Sida · Contactinfo@fls-rs.com · +34934978414
    • Anna Prats, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — The individual participant data (IPD) will not be shared publicly due to the nature of the study, the limited sample size, and the sensitive nature of the data related to cognitive status of the participants.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Nov 2026, 4 months after the start.

Of 232 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 4 months is below that.

Counting every sponsor, half of 243 studies reached it within 16 months; a quarter within 7 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2026
First posted
Apr 15, 2026
StartActual
Jul 15, 2026
Primary completionEst.
Nov 2026
CompletionEst.
Apr 2027
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07530757
Lead sponsor
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Collaborators
Fundació Institut Germans Trias i Pujol
Responsible party
Sponsor
First posted
Apr 15, 2026
Start date
Jul 15, 2026
Primary completion
Nov 2026 (estimated)
Completion
Apr 2027 (estimated)
Last update
Sep 11, 2026

Study contacts

Anna Prats, PhD
Contact
aprats@lluita.org
+34934657897
David Rovira
Contact
drovira@scienhub.org
+34934978849
Anna Prats, PhD
principal investigator · Fundació Lluita contra les Infeccions

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion